Robert McNamara
Robert McNamara's purchase track record
How the stock did after each of Robert McNamara's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/28/2025 | RCEL | $45K | -15.5% | +16.7% | +6.3% |
| 8/19/2025 | RCEL | $50K | -18.9% | -11.5% | +6.7% |
| 3/6/2025 | RCEL | $91K | -30.5% | -48.1% | +13.3% |
| 2/20/2025 | RCEL | $101K | -35.7% | -52.3% | +4.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Alpha Teknova Shares Rise 7.1% Amid Technical Momentum. Alpha Teknova stock moved 7.1% higher recently, a gain that has raised questions about the sustainability of this strength. The move coincides with a Bollinger Band breakout signal, indicating increased volatility and momentum. While the stock is trading well above its recent support levels, the rapid rise has pushed the RSI into overbought territory, suggesting the pace of gains may be intense.
Transaction History
| RCEL | ▲ Buy | Grant | 22,214 | — | 1/20/2026 | View on chart |
| RCEL | ▲ Buy | Open Market | 10,000 | $45K | 8/28/2025 | View on chart |
| RCEL | ▲ Buy | Open Market | 10,000 | $50K | 8/19/2025 | View on chart |
| RCEL | ▲ Buy | Open Market | 11,000 | $91K | 3/6/2025 | View on chart |
| RCEL | ▲ Buy | Open Market | 10,000 | $101K | 2/20/2025 | View on chart |
| RCEL | ▲ Buy | Grant | 10,022 | — | 1/21/2025 | View on chart |
| RCEL | ▲ Buy | Grant | 10,000 | $90K | 8/19/2024 | View on chart |
| XTNT | ▲ Buy | Grant | 162,162 | $0 | 8/15/2024 | View on chart |
| RCEL | ▲ Buy | Grant | 9,200 | — | 6/5/2024 | View on chart |
| TKNO | ▼ Sell | Other | 18,815 | $0 | 8/31/2023 | View on chart |
| XTNT | ▲ Buy | Grant | 145,180 | $0 | 8/15/2023 | View on chart |
| RCEL | ▲ Buy | Grant | 6,175 | — | 6/6/2023 | View on chart |
| RCEL | ▲ Buy | Grant | 10,374 | — | 6/6/2023 | View on chart |
| TKNO | ▲ Buy | Grant | 18,815 | $0 | 6/2/2023 | View on chart |
| XTNT | ▲ Buy | Grant | 215,415 | $0 | 8/15/2022 | View on chart |
| TKNO | ▲ Buy | Grant | 9,357 | $0 | 6/2/2022 | View on chart |
| XTNT | ▲ Buy | Grant | 85,337 | $0 | 8/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat
PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.
RCEL Gains Fair Value Lift After PermeaDerm Data and Q2 Beat. PermeaDerm data and a Q2 earnings beat lifted RCEL’s fair value. The news gave the stock a positive momentum boost. The lift comes as the company reports stronger‑than‑expected results and promising data from its PermeaDerm platform. The move is a short‑term reaction to the earnings beat and data release.